1447962-89-1Relevant academic research and scientific papers
Synthesis of two-photon active cinnamoyl coumarins for high-contrast imaging of cancer cells and their photophysical characterization
Yadav, Preeti,Satapathi, Soumitra,Kumari, Meena,Chaturvedi, Akanksha,Li, Lian,Samuelson, Lynne A.,Kumar, Jayant,Sharma, Sunil K.
, p. 39 - 45 (2014)
A series of two-photon (TP) active 4-dimethylaminocinnamoyl coumarins were synthesized. These compounds exhibit red shift in absorption and considerable Stokes shift in emission spectra in comparison to the parent coumarin. Large TP absorption cross-sections were measured for all the coumarins in dilute solutions. A correlation between the chemical structure and TP characteristics was established. TP confocal microscopy revealed that these coumarin derivatives can be internalized by cancer cells rendering them a potential candidate as a label in TP confocal imaging.
Synthesis and antiproliferative and c-Src kinase inhibitory activities of cinnamoyl-and pyranochromen-2-one derivatives
Chand, Karam,Shirazi, Amir Nasrolahi,Yadav, Preeti,Tiwari, Rakesh K.,Kumari, Meena,Parang, Keykavous,Sharma, Sunil K.
, p. 741 - 754 (2013/08/23)
A series of 6-and 8-cinnamoylchromen-2-one and dihydropyranochromen-2-one derivatives were synthesized and their antiproliferative activities were evaluated against three human cancer cell lines, i.e., ovarian adenocarcinoma (SK-OV-3), leukemia (CCRF-CEM), and breast carcinoma (MCF-7). In general, 8-cinnamoylchromen-2-one derivatives were found to have higher antiproliferative activity against the cancer cells when compared with 6-cinnamoyl analogues. Among all of the hybrid chromen-2-one-chalcone/flavanone compounds, a 7-hydroxy-8-cinnamoylchromen-2-one derivative 35 was found to be consistently active against all the cancer cell lines and inhibited the cell proliferation of SK-OV-3, CCRF-CEM, and MCF-7 by 63%, 50%, and 43%, respectively, at a concentration of 50 μmol/L after 72 h of incubation. This compound also exhibited the highest Src kinase inhibition (IC50 = 14.5 μmol/L). Structure-activity relationship studies provided insights for designing the next generation of chromen-2-one-chalcone hybrid prototypes and the development of new leads as anticancer agents and (or) Src kinase inhibitors.
